Nan Cheng

Discovery of LB10, a Potent and Orally Bioavailable Inhibitor of Ecto-5′-Nucleotidase as a Single Agent or in Combination for the Treatment of Lung Cancer

Ecto-5-nucleotidase (CD73), a rate-limiting enzyme in the adenosine pathway, plays a crucial role in mediating tumor immunosuppression and has emerged as an attractive target for cancer immunotherapy. A series of aryl alkyl ether-based CD73 inhibitors were designed and synthesized. Compound LB10 stood out as the most...